FDA Approves Fourth Biosimilar Drug Amjevita

The Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto; Amgen) as a biosimilar to Humira (adalimumab; AbbVie) for various inflammatory diseases.

BLA Submitted for Investigational RA Drug

Janssen Biotech announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for the approval of sirukumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

AACE/ACE: New Guidelines for Postmenopausal Osteoporosis Management

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other healthcare professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis

Propranolol Explored as Possible Tardive Dyskinesia Treatment

A new retrospective study found evidence which suggests that the β-adrenergic blocker propranolol, may be an effective treatment for tardive dyskinesia (TD), for which there are no current approved treatments.

Antihypertensive Drug Class May Impact Fracture Risk in Older Patients

The use of angiotensin receptor blocker (ARBs) in older men with hypertension was associated with a reduced incidence of non-vertebral fracture than angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs), according to a study published in Age and Ageing.

C. Difficile/Oral Bisphosphonate Link Examined Using FDA Reporting System

Compared to other bisphosphonates, alendronate was associated with a higher number of Clostridium difficile infection (CDI) adverse drug reactions, as indicated by the Food and Drug Administration (FDA) Adverse Event Reporting System data (FAERS).

Popular Alternative Therapies Effective for Certain Pain Conditions

The pain conditions included back pain, neck pain, osteoarthritis, fibromyalgia, severe headaches and migraine.

Can Lesinurad Added to Allopurinol Lower Serum Urate in Gout Patients?

Adding lesinurad to allopurinol provided extra benefit vs. allopurinol alone in lower serum urate (sUA) levels and is an option for patients requiring additional urate-lowering, a study published in Arthritis & Rheumatology reported.

FDA Approves First Biosimilar to Enbrel

The Food and Drug Administration (FDA) has approved Erelzi (etanercept-szzs; Sandoz) injection, a biosimilar to Enbrel (etanercept; Amgen).

Glucocorticoid Inj Permanently Discontinued

The Food and Drug Administration (FDA) is informing about the permanent discontinuation of Aristospan (triamcinolone hexacetonide injectable suspension; Sandoz).

Methotrexate Monotherapy, Combo Therapy Compared for RA

Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.

Drug Therapies Compared for Glucocorticoid-Induced Osteoporosis

Amgen announced top-line data from a primary analysis conducted in a Phase 3 study evaluating the safety and efficacy of Prolia (denosumab) vs. risedronate in patients receiving glucocorticoid treatment.

Myopathy: Another Side Effect of PPIs?

Limited research published in Annals of Pharmacotherapy suggests that use of proton pump inhibitors (PPI) is associated with myopathy-like symptoms without long-term effects after discontinuation.

Ultrasonography Assessed as Drug Guiding Modification for Arthritis

Ultrasonography can be useful for guiding modification of anti-rheumatic drugs and steroids for patients with inflammatory arthritis (IA), according to a study published online in the International Journal of Rheumatic Diseases.

Synacthen Depot Fast-Tracked for Duchenne Muscular Dystrophy

Mallinckrodt announced that the FDA has granted Fast Track designation to the Investigational New Drug (IND) application of Synacthen Depot (tetracosactide) for the treatment of Duchenne muscular dystrophy (DMD).

Use of Drugs Linked with Fracture Risk Evaluated Post-Fracture

Exposure to prescription drugs associated with fracture risk was not consistently reduced after a fragility fracture occurrence, researchers reported in a JAMA Internal Medicine article.

FDA Designates Dusquetide Orphan Drug for Life-Threatening Immune Disorder

The FDA has granted Orphan Drug designation to dusquetide (SGX942; Soligenix) for the treatment of macrophage activation syndrome (MAS), a life-threatening complication of rheumatic disease.

Experimental Drug Reduces Fracture Risk Better than Existing Therapy in Osteoporosis Study

In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo, according to a study published in the Journal of the American Medical Association.

Investigational Muscle Protein Designated Orphan Drug for DMD

The FDA has granted Orphan Drug designation to TVN-102 (Tivorsan), previously referred to as recombinant human Biglycan, for the treatment of Duchenne Muscular Dystrophy (DMD).

DASH Diet May Benefit Gout Patients

A study published in Arthritis & Rheumatology has found that the DASH diet reduced serum uric acid, particularly in patients with hyperuricemia.

Gout Flares With Arhalofenate Vs Allopurinol Examined in Study

Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology.

Thymectomy Tied to Multiple Benefits in Myasthenia Gravis

Thymectomy improves clinical outcomes over a three-year period in patients with nonthymomatous myasthenia gravis, according to research published in the Aug. 11 issue of the New England Journal of Medicine.

FDA Grants Priority Review to Deflazacort for Duchenne Muscular Dystrophy

The FDA has accepted for filing and granted Priority Review to the New Drug Applications (NDA) of deflazacort immediate-release tablet and oral suspension formulations for the treatment of Duchenne Muscular Dystrophy (DMD).

FDA Approves Updated ONJ Warning for Prolia, Xgeva

The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).

Gelsyn-3 Now Available for Knee Osteoarthritis Pain

Bioventus announced the availability of Gelsyn-3 (hyaluronic acid), an injectable indicated for pain associated with osteoarthritis of the knee.

Hand, Hip, and Knee Osteoarthritis Risks Increase in Tandem With Weight

The incidence of hand, hip, and knee osteoarthritis (OA) increases with overweight and obesity, particularly in the knee, according to a study published in Arthritis & Rheumatology.

Ustekinumab Significantly Improves Patient-Reported Outcomes in PsA

Significant improvements in patient-reported outcomes (PROs) were seen with ustekinumab vs. placebo in 3 antecedent-exposure populations of patients with psoriatic arthritis, including those with prior methotrexate and anti-tumor-necrosis factor (TNF) use, according to findings from a study published in Arthritis Care & Research.

Interchangeability of Biosimilar and Reference TNF-α Inhibitors Examined

Preliminary data from a systematic review supported the biosimilarity and interchangeability of biosimilar and reference tumor necrosis factor alpha (TNF-α) inhibitors.

Dysport Approved for Pediatric Lower Limb Spasticity

Ipsen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in patients aged ≥2 years. This approval marks Dysport as the first FDA-approved botulinum toxin for this indication.

Gout Management Updates Reflect New Treatments

The European League Against Rheumatism (EULAR) have updated their recommendations on the management of gout to reflect novel treatments and evidence surrounding already established treatments.

Analysis Identifies Uveitis Risk Factors in Ankylosing Spondylitis Patients

An analysis published in Medicine identified hip-joint lesion, prevalence of peripheral arthritis, and antistreptolysin O (ASO) and circulating immune complex (CIC) levels as risk factors that may be tied to higher rates of uveitis in ankylosing spondylitis.

Study Examines Efficacy of Ultrasound-Guided Treatment for Trigger Finger

An ultrasonographically (US)-guided percutaneous treatment using a 21-gauge needle is efficacious for trigger finger, according to a study published in the August issue of Radiology.

FDA to Review Investigational Bone-Forming Monoclonal Antibody for Osteoporosis

Amgen and UCB announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Lab-Grown Cartilage Moves Closer to Being Hip Replacement Option

Progress has been made toward developing lab-grown cartilage that could postpone or possibly eliminate the need for hip replacement surgery in younger arthritis patients, according to research published online in the Proceedings of the National Academy of Sciences.

RA Drug Available in New Autoinjector Device

Bristol-Myers Squibb announced the launch of Orencia (abatacept) ClickJect Autoinjector, a new autoinjector for adults with moderate to severe rheumatoid arthritis.

Aleve Direct Therapy Device Available OTC for Lower Back Pain

Bayer announced the launch of Aleve Direct Therapy, a drug-free, pain relief device.

Vagus Nerve Stimulation May Help Ease RA Symptoms

Electronic stimulation of the vagus nerve may help ease symptoms of rheumatoid arthritis (RA), according to a study published online in the Proceedings of the National Academy of Sciences.

Risky Whole Body Cryotherapy Growing in Popularity

The Food and Drug Administration (FDA) is warning against misleading claims about whole body cryotherapy to treat various diseases or conditions.

CDC: Arthritis Prevalence May Rise To 78.4 Million By 2040

The prevalence of arthritis and arthritis-attributable activity limitation is projected to increase in U.S. adults by 2040, according to a study published online in Arthritis & Rheumatology.

DPP-4 Inhibitors Linked to Improved Vitamin D Balance in T2DM Patients

Findings from a study published in Acta Diabetologica support that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with better vitamin D balance in patients with type 2 diabetes.

Do TNF Inhibitors Offer CV Benefits in Psoriasis, Psoriatic Arthritis?

In a study published in Clinical Reviews in Allergy & Immunology, researchers found that tumor necrosis factor (TNF inhibitors appeared to have clinical benefits with regard to adverse cardiovascular events in psoriasis and/or psoriatic arthritis.

Study Sheds Light on Link Between Immunotherapy and Arthritis Onset

A new study has shed light on an association between immune checkpoint inhibitors (ICIs) and the onset of inflammatory arthritis and sicca syndrome.

Hypertension, Pain Combo Drug Shown Beneficial on Kidney Function

Kitov Pharmaceuticals announced new study data from the Phase 3 study for KIT-302 (amlodipine besylate/celecoxib) in the treatment of osteoarthritis pain and hypertension, suggesting beneficial effects on renal function.

Does Prior TNFi Use Affect Secukinumab Effectiveness in Psoriatic Arthritis?

Secukinumab, a human anti-IL-17A monoclonal antibody, was shown to be effective in both tumor necrosis factor inhibitor (TNFi)-naïve and TNFi-exposed psoriatic arthritis patients, however greater improvements were noted in TNFi- naïve patients.

Higher Allopurinol Dose May be Nephroprotective in Elderly

A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases.

Tocilizumab vs. Methotrexate Compared in Newly Diagnosed RA Patients

Immediate initiation with tocilizumab with or without methotrexate was more effective than methotrexate alone for patients with newly diagnosed rheumatoid arthritis, researchers concluded in a study published in The Lancet.

FDA to Review Deflazacort for Duchenne Muscular Dystrophy

Marathon Pharmaceuticals announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for deflazacort for the treatment of patients with Duchenne Muscular Dystrophy (DMD).

Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs

Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.

Carpal Tunnel Function, Dexterity Improved With Electroacupuncture

Electroacupuncture may be a beneficial treatment option for carpal tunnel syndrome, according to a study published online June 6 in CMAJ, the journal of the Canadian Medical Association.

Sirukumab Inhibits Joint Destruction, Improves RA Symptoms, Study Shows

Janssen announced positive results from the SIRROUND-D study, a pivotal Phase 3 trial evaluating subcutaneous sirukumab (CNTO 136) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

Biologics May Improve Fatigue in Rheumatoid Arthritis

For patients with rheumatoid arthritis (RA), biological interventions of both anti-tumor necrosis factor (anti-TNF) and non-anti-TNF agents may lead to a small to moderate improvement in fatigue.

Promising Results for Xeljanz as Potential Psoriatic Arthritis Tx

Pfizer announced top-line results from the OPAL Beyond study, the second Phase 3 trial of Xeljanz (tofacitinib citrate) for the potential treatment of patients with active psoriatic arthritis (PsA).

Cannabinoids May Benefit Pain, Sleep Issues For Rheumatic Patients

Cannabinoids may have limited benefits in rheumatic conditions, with some potential benefit in terms of pain relief and effect on sleep, according to a review published in Arthritis Care & Research.

Adherence Rates for Combination Therapies in RA Compared

Veterans with rheumatoid arthritis were significantly more likely to be persistent and adherent to a tumor necrosis factor inhibitor (TNFi) plus methotrexate combination therapy than to triple therapy with non-biologic disease-modifying antirheumatic drugs (DMARDs), a study published in Arthritis Care & Research concluded.

FDA Continues Review of Controversial DMD Treatment

Sarepta announced that the Food and Drug Administration (FDA) is continuing the pending New Drug Application (NDA) review for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Biosimilar Candidate to Remicade Under FDA Review

The FDA has accepted for review the Biologics License Application (BLA) for SB2 (Samsung Bioepis), a biosimilar candidate to Remicade (infliximab; Janssen), for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Risk Factors for Bisphosphonate-Associated Fractures, Osteonecrosis ID'd

Use of bisphosphonates is associated with adverse drug reactions such as atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ).

Which Fluoroquinolone Antibiotic Carries the Greatest Risk of Tendinopathy?

Given the widespread use of fluoroquinolone antibiotics, clinicians should be aware of factors that may put patients at increased risk for tendinitis or tendon rupture, according to an article published in Pharmacotherapy.

Preventing Anemia After Orthopedic Surgery: The Role of Iron, ESA Pharmacotherapy

The use of intravenous (IV) or oral iron with or without an erythropoiesis-stimulating agent (ESA) may help prevent post-operative anemia and reduce blood transfusion without significantly raising the risk of adverse events, study authors reported in a study published in Annals of Pharmacotherapy.

FDA Grants Priority Review to Advanced Soft Tissue Sarcoma Tx

The FDA has granted Priority Review for the Biologics License Application (BLA) for olaratumab (Lilly), in combination with doxorubicin, for the potential treatment of advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.

FDA Advisory Committee Votes Against DMD Drug Approval

A majority of The Food and Drug Administration's (FDA) Advisory Committee voted against recommending eteplirsen, which in its New Drug Application (NDA), proposes to become the first drug to treat Duchenne muscular dystrophy.

Gene Variant Linked to Severe Cutaneous Reactions with Gout Treatment

Findings from a new study published in Seminars in Arthritis and Rheumatism show significant racial disparities in the risk of gout patients developing a serious, sometimes fatal adverse reaction to urate-lowering drugs.

REMS Requirement Removed for Gout Drug

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Krystexxa (pegloticase; Horizon) Injection.

New Biosimilar Inflectra Gets FDA Approval

The Food and Drug Administration (FDA) has approved Inflectra (infliximab-dyyb; Celltrion) for injection, a biosimilar to Remicade (infliximab; Janssen).

Certain ADHD Drugs May Lower Bone Density

Youth who take stimulants to treat attention deficit hyperactivity disorder (ADHD) may have a lower bone density than their peers who do not take stimulants, according to a study presented at ENDO 2016.

Certain Antidepressants May Up Bone Loss During Lactation

Selective serotonin reuptake inhibitors (SSRIs) use during pregnancy and lactation can result in decreased bone density in mothers, increasing their risk of fractures later in life, a study presented at ENDO 2016 has found.

Radius Submits NDA for New Osteoporosis Tx in Postmenopausal Women

Radius Health announced the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for abaloparatide-subcutaneous (SC) 80mg, a once daily treatment for postmenopausal women with osteoporosis.

Arthritis Patients May Be More Prone to Developing Periodontitis

Rheumatoid arthritis (RA) patients have a greater prevalence and severity of periodontitis than the non-arthritis population, according to a new study published in the Korean Journal of Internal Medicine.

Febuxostat vs. Allopurinol for the Prevention of Tumor Lysis Syndrome

The efficacy and safety of febuxostat was noninferior to allopurinol for preventing tumor lysis syndrome (TLS) in patients with malignant tumors about to receive chemotherapy, according to a new study published in the journal, Oncology.

Promising Results for Romosozumab in Men with Osteoporosis

Amgen and UCB announced positive top-line results from the pivotal Phase 3 study, BRIDGE, evaluating romosozumab for the treatment of osteoporosis in men.

Vaccination Recommendations for RA Patients on DMARD Therapy

Vaccination rates in patients with rheumatoid arthritis remain poor "despite the high rates of infectious disease-related morbidity and mortality," a review published in Clinical Opinion in Rheumatology has found.

Efficacy of NSAIDs Compared for Osteoarthritis Pain

Diclofenac 150mg per day was determined as the most effective non-steroidal anti-inflammatory drug (NSAID) available for improving both pain and function in patients with osteoarthritis, according to a study published in The Lancet.

Corticosteroid Injection Currently in Shortage

The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).

Investigational Treatment Shows Superiority in RA Study

Regeneron and Sanofi announced their Phase 3 study for sarilumab has met its primary endpoint, demonstrating superiority over adalimumab in improving symptoms in patients with active rheumatoid arthritis (RA) at Week 24, in the SARIL-RA-MONARCH trials.

Study Tests Potential Benefits of Vitamin D Supplementation in Knee Osteoarthritis

For patients with knee osteoarthritis, supplementation with vitamin D does not slow cartilage loss or alleviate knee pain.

Long-Term Safety Data for Otezla Announced

Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology's Annual Meeting.

Study Reveals Negative BMD Association With ADHD Meds in Adolescents

A significant difference in bone mineral density (BMD) was noted in patients aged 8-17 who have used ADHD medication, compared to their same aged counterparts who have not taken the medication.

Survey Reveals Docs Prescribing Preferences for Osteoporosis Tx

A recent online survey has found that physicians in the United States tend to prefer weekly or monthly regimens when prescribing treatment for patients with osteoporosis.

Top-Line Results for Investigational Osteoporosis Tx Announced

Amgen and UCB announced top-line results from the Phase 3 FRAME study evaluating the safety and efficacy of romosozumab for the treatment of osteoporosis in postmenopausal women.

Osteoporosis Tabs Recalled Due to Unknown Impurity Levels

Sun Pharma announced a recall of Alendronate Sodium Tablets 70mg, the generic version of Fosamax.

Third Orphan Drug Designation Granted to TXA127 in Muscular Dystrophy

The Food and Drug Administration (FDA) has granted Orphan Drug designation to TXA127 (Tarix Orphan) for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A).

Glucosamine, Chondroitin Sulfate Provides Long-Term Protection in Knee OA

Findings from a recent study published in Arthritis Care & Research support the long-term protective effects of glucosamine/chondroitin sulfate on the progression of structural changes in knee osteoarthritis.

Vivlodex Now Available for Osteoarthritis Pain

Iroko announced that Vivlodex (meloxicam) capsules is now available for the management of osteoarthritis (OA) pain.

Xeljanz Released from REMS Requirement

The FDA has approved a supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib; Pfizer) to eliminate the requirement for the approved Risk Evaluation and Mitigation Strategy (REMS) assessment.

Advisory Panel Recommends Approving Biosimilar of Remicade

Celltrion announced that the Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of all indications for CT-P13, a biosimilar candidate of Remicade (infliximab; Janssen Biotech).

New Dosage Strength of Xeomin Launched

Merz Neurosciences announced the launch of Xeomin (incobotulinumtoxinA) in a new 200 Unit single-dose vial.

New Study Proposes Strategies for Pain Control After Total Knee Replacement

A team-based care approach comprised of the patient, family members, orthopedic surgeon, and other healthcare practitioners for total knee replacement procedures, combined with newer pain management strategies, is critical for maximizing patient outcomes.

BLA for Adalimumab Biosimilar Accepted for Review

Amgen announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira (adalimumab).

Study Shows Majority of Gout Patients Unaware of Treatment Goals

A new study has highlighted a possible knowledge-gap between healthcare professionals and gout patients, concerning their condition.

Botox Gains Lower Limb Spasticity Indication

Allergan announced that the Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of lower limb spasticity in adults to decrease the severity of increased muscle stiffness in ankle and toe muscles.

Guidance on Long-Term Bisphosphonate Tx for Osteoporosis Issued

A task force of the American Society for Bone and Mineral Research has issued guidance on the bisphosphonate therapy for osteoporosis with a risk-benefit perspective.

FDA to Review Once-Daily Oral RA Tx

Eli Lilly and Incyte announced that the New Drug Application (NDA) for once-daily oral baricitinib has been submitted to the Food and Drug Administration (FDA) for the treatment of moderately-to-severely active rheumatoid arthritis (RA).

Cosentyx Gains Two New Arthritis Indications

Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

FDA Issues Complete Response Letter to Kyndrisa

The Food and Drug Administration (FDA) has issued a Complete Response Letter to the New Drug Application (NDA) for Kyndrisa (drisapersen; Biomarin), for the treatment of Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping.

Cancer, RA Biosimilars Demonstrated Efficacy in Phase 3 Trials

Sorrento Therapeutics announced that its partner, MabTech, has successfully completed Phase 3 clinical trials in China for STI-001, a biosimilar antibody for cetuximab (Erbitux).

NDA for First-in-Class DMD Tx Submitted to FDA

PTC Therapeutics announced the completion of its rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

Physicians Advised to Rethink Preference for Osteoporosis 'Drug Holiday'

The International Osteoporosis Foundation (IOF) has advised physicians to make treatment decisions more individualized for patients taking bisphosphonates; a class of drugs used to treat osteoporosis.

Xeomin Approved for Adult Upper Limb Spasticity

Merz North America announced that Xeomin (incobotulinumtoxinA) has been approved by the Food and Drug Administration (FDA) for the treatment of upper limb spasticity in adults.

New Gout Treatment Gets FDA Approval

The FDA has approved Zurampic (lesinurad; AstraZeneca) to treat hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI).

For Active Individuals, Higher Vit D Levels May Be Needed

Individuals who participate in higher impact activities may require higher vitamin D levels to reduce their risk of stress fractures, a new study in The Journal of Foot & Ankle Surgery reported.